Alice Tsang Shaw, MD, PhD (Damon Runyon Fellow ‘04-‘05) of Massachusetts General Hospital, Boston, and colleagues, reported that treatment with the investigational drug LDK378 resulted in an overall response rate of 60% to 78% in patients with advanced non-small cell lung cancer (NSCLC) with mutations in the anaplastic lymphoma kinase (ALK) gene. In March, LDK378 received Breakthrough Therapy designation from the US Food and Drug Administration (FDA). These results were presented at the annual meeting of the American Society of Clinical Oncology (ASCO).